Korro Bio’s (KRRO) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Korro Bio (NASDAQ:KRRO) in a research note issued to investors on Wednesday morning,RTT News reports.

A number of other research analysts also recently weighed in on KRRO. Raymond James initiated coverage on shares of Korro Bio in a report on Monday, October 21st. They set a “strong-buy” rating and a $153.00 price target on the stock. HC Wainwright raised their target price on shares of Korro Bio from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Finally, Royal Bank of Canada raised their target price on shares of Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, October 21st. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $142.17.

Korro Bio Stock Down 4.3 %

KRRO stock traded down $2.14 during midday trading on Wednesday, reaching $47.56. The company had a trading volume of 91,603 shares, compared to its average volume of 69,920. Korro Bio has a 1 year low of $30.00 and a 1 year high of $98.00. The company has a 50 day moving average of $50.05 and a two-hundred day moving average of $46.85.

Korro Bio (NASDAQ:KRRO) last released its earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.55) by $0.29. On average, equities analysts anticipate that Korro Bio will post -10.02 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Vineet Agarwal sold 10,216 shares of Korro Bio stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $78.26, for a total transaction of $799,504.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Korro Bio

Several institutional investors have recently added to or reduced their stakes in KRRO. Brown Brothers Harriman & Co. bought a new position in Korro Bio during the 2nd quarter valued at about $28,000. Quest Partners LLC raised its stake in shares of Korro Bio by 172.1% in the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after acquiring an additional 1,124 shares during the last quarter. Vestcor Inc bought a new position in shares of Korro Bio in the third quarter worth about $100,000. MetLife Investment Management LLC raised its stake in shares of Korro Bio by 129.0% in the third quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock worth $122,000 after acquiring an additional 2,050 shares during the last quarter. Finally, Lynx1 Capital Management LP bought a new position in shares of Korro Bio in the second quarter worth about $129,000. 13.18% of the stock is owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).